***Commonwealth of Massachusetts***

***Executive Office of Health and Human Services***

***Office of Medicaid***

[*www.mass.gov/masshealth*](http://www.mass.gov/masshealth)

MassHealth

# All Provider Bulletin 328

November 2021

**TO**: All Providers Participating in MassHealth

**FROM**: Amanda Cassel Kraft, Assistant Secretary for MassHealth [signature of Amanda Cassel Kraft]

RE: Coverage for Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccines

## **MassHealth Coverage of COVID-19 Vaccine Booster Doses**

On September 22, 2021, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to allow a booster shot for certain high-risk individuals[[1]](#footnote-1) administered at least six months after completing the primary series. On October 20, 2021, the FDA amended the EUA for the Moderna COVID-19 vaccine to allow a booster shot for the same listing of high-risk individuals at least six months after completing the primary series and the EUA for the Janssen COVID-19 vaccine to allow a single booster dose at least two months after the primary vaccination to individuals 18 years of age or older. The FDA also amended the EUAs for the Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines to allow an authorized booster dose as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine.

MassHealth will cover booster doses of the BioNTech, Moderna, and Janssen COVID-19 vaccines consistent with the EUAs. MassHealth expects it will pay $45.87 for the administration of booster doses, the same rate it pays for the administration of all other doses of COVID-19 vaccine.

The following new codes will be covered by MassHealth at the following expected rates.

|  |  |  |  |
| --- | --- | --- | --- |
| **Code** | **Description** | **Expected Rate** | **Effective Date** |
| 0004A | Pfizer-BioNTech Covid-19 Vaccine Administration – Booster | $45.87 | 09/22/2021 |
| 0064A | Moderna Covid-19 Vaccine (Low Dose) Administration - Booster | $45.87 | 10/20/2021 |
| 91307 SL | Moderna Covid-19 Vaccine (Low Dose) | $0.00 | 10/20/2021 |

No codes are being added for the Janssen vaccine booster dose; the existing codes 91303 SL and 0031A can be used. Similarly, no new code for the booster dose of the vaccine itself is being added for Pfizer-BioNTech; the existing vaccine code 91300 SL can be used.

There is no cost sharing for any COVID-19 vaccines. Rates and billing codes will be established through an administrative bulletin or the promulgation of emergency regulations by the Executive Office of Health and Human Services.

This bulletin applies to members enrolled in MassHealth fee-for-service, the Primary Care Clinician (PCC) Plan, or a primary care accountable care organization (ACO). Information about coverage through MassHealth managed care entities (MCEs) and the Program for All-inclusive Care for the Elderly (PACE) will be included in a forthcoming MCE bulletin.

## MassHealth Website

This bulletin is available on the [MassHealth Provider Bulletins](http://www.mass.gov/masshealth-provider-bulletins) web page.

[Sign up](https://www.mass.gov/forms/email-notifications-for-masshealth-provider-bulletins-and-transmittal-letters) to receive email alerts when MassHealth issues new bulletins and transmittal letters.

## Questions

### Dental Services

Phone: (800) 207-5019; TTY: (800) 466-7566

### Long-Term Services and Supports

Phone: (844) 368-5184 (toll free)

Email: support@masshealthltss.com

Portal: [MassHealthLTSS.com](https://www.masshealthltss.com/s/?language=en_US)

Mail: MassHealth LTSS
PO Box 159108
Boston, MA 02215

Fax: (888) 832-3006

### All Other Provider Types

Phone: (800) 841-2900; TTY: (800) 497-4648

Email: providersupport@mahealth.net

Fax: (617) 988-8974

1. The EUA references the following individuals as qualifying:

individuals 65 years of age and older;

individuals 18 through 64 years of age at high risk of severe COVID-19; and

individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19. [↑](#footnote-ref-1)